

What Is Claimed Is:

Subt A3
 1. ~~A vector capable of tissue-specific replication comprising:
 a tissue-specific transcriptional regulatory sequence operably linked to the
 coding region of a gene that is essential for replication of said vector.~~

5 2. The vector of claim 1, wherein the transcriptional regulatory
 sequence is selected from the group consisting of promoters and enhancers.

3. The vector of claim 2, wherein said promoter is selected from the
 group consisting of α -fetoprotein, DF3, tyrosinase, CEA, surfactant, ^{protein} and ErbB2. ^{PROMOTERS}

10 4. The vector of claim 1, wherein said vector is a DNA tumor viral
 vector.

5. The vector of claim 4, wherein said DNA tumor viral vector is
 selected from the group consisting of *Herpesvirus*, Papovavirus, papillomavirus,
 hepatitis virus, and parvovirus.

15 6. The vector of claim 4, wherein said DNA tumor viral vector is an
 adenovirus vector.

Subt A4
 7. ~~The vector of claim 6, wherein said coding region is selected from
 the group consisting of E1a, E1b, and E2 and E4 coding regions.~~

8. The vector of claim 1, wherein said vector contains a heterologous
 coding sequence that is ~~capable of being~~ expressed from said vector.

20 Subt A5
 9. ~~A method for distributing a polynucleotide in a tissue *in vivo*,
 comprising introducing a replication-conditional vector containing said~~

4th

-47-

polynucleotide into said tissue, wherein said vector contains a gene essential for vector replication, the coding region of which gene is operably linked to a transcriptional regulatory sequence that functions specifically in said tissue so that replication of the vector occurs in said tissue and not in a tissue in which said transcriptional regulatory sequence does not function.

10. The vector of claim 9, wherein the transcriptional regulatory sequence is selected from the group consisting of promoters and enhancers.

11. The vector of claim 10, wherein said promoter is selected from the group consisting of α -fetoprotein, DF3, tyrosinase, CEA, surfactant, and ErbB2.

12. The method of claim 9, wherein said tissue is tumor tissue.

13. The method of claim 9, wherein said vector is a DNA tumor viral vector.

14. The method of claim 13, wherein said DNA tumor viral vector is selected from the group consisting of *Herpesvirus*, Papovavirus, papillomavirus, parvovirus, and hepatitis virus.

15. The method of claim 14, wherein said vector is an adenovirus vector.

16. The method of claim 15, wherein said coding region that is operably linked to said transcriptional regulatory sequence is selected from the group consisting of E1a, E1b, E2, and E4 coding regions.

17. The method of claim 9, wherein said vector encodes a heterologous gene product, and wherein said vector expresses said heterologous gene product in the cells of said tissue.

18. The method of claim 17, wherein said heterologous gene product provides anti-tumor activity in the cells of said tissue.

19. A cell containing a vector capable of tissue-specific replication, said vector comprising
a tissue-specific transcriptional regulatory sequence operably linked to the coding region of a gene that is essential for replication of said vector, wherein said transcriptional regulatory sequence functions in said cell so that replication of the vector occurs in said cell.

20. The ⁴isolated ⁵cell of claim 19, wherein said transcriptional regulatory sequence is selected from the group consisting of promoters and enhancers.

21. The ⁷isolated ⁴cell of claim 20, wherein said promoter is selected from the group consisting of α -fetoprotein, DF3, tyrosinase, CEA, surfactant^{protein}, and ErbB2^{promoters}.

22. The ⁶isolated ⁵cell of claim 19, wherein said cell is a tumor cell.

23. The cell of claim 19, wherein said vector is a DNA tumor viral vector.

24. The cell of claim 23, wherein said DNA tumor viral vector is selected from the group consisting of *Herpesvirus*, Papovavirus, papillomavirus, parvovirus, and hepatitis virus.

25. The cell of claim 24, wherein said vector is an adenovirus vector.

Subt
a8
a
5
26. ~~The cell of claim 25, wherein said coding region that is operably linked to said transcriptional regulatory sequence is selected from the group consisting of E1a, E1b, E2, and E4 coding regions.~~

9 isolated 5
27. The cell of claim 19, wherein said vector encodes a heterologous gene product, and wherein said vector expresses said heterologous gene product in the cells of a target tissue.

10 isolated 9
28. The cell of claim 27, wherein said heterologous gene product provides anti-tumor activity in the cells of said tissue.

Subt
a9
10
29. ~~A method of producing a vector capable of tissue-specific replication, said vector comprising a tissue-specific transcriptional regulatory sequence operably linked to the coding region of a gene that is essential for replication of said vector, comprising culturing the cell of claim 19 and recovering said vector from said cell.~~

15
30. A cell containing a virion capable of tissue-specific replication, said virion comprising

a tissue-specific transcriptional regulatory sequence operably linked to the coding region of a gene that is essential for replication of said virion, wherein said transcriptional regulatory sequence functions in said cell so that replication of the virion occurs in said cell.

13 isolated 12
31. The cell of claim 30, wherein said transcriptional regulatory sequence is selected from the group consisting of promoters and enhancers.

14 isolated 13
32. The cell of claim 31, wherein said promoter is selected from the group consisting of α -fetoprotein, DF3, tyrosinase, CEA, surfactant, and ErbB2. ^{protein} ^{promoters}

¹⁵
~~33.~~ isolated ¹²

The cell of claim ~~30~~, wherein said cell is a tumor cell.

~~34. The cell of claim 30, wherein said virion is a DNA tumor viral virion.~~

35. The cell of claim 34, wherein said DNA tumor viral virion is selected from the group consisting of *Herpesvirus*, Papovavirus, papillomavirus, parvovirus, and hepatitis virus.

36. The cell of claim 35, wherein said virion is an adenovirus virion.

^{Subt}
~~37. The cell of claim 36, wherein said coding region that is operably linked to said transcriptional regulatory sequence is selected from the group consisting of E1a, E1b, E2, and E4 coding regions.~~

¹⁶
~~38.~~ isolated ¹²

The cell of claim ~~30~~, wherein said virion encodes a heterologous gene product, and wherein said virion expresses said heterologous gene product in the cells of a target tissue.

¹⁷
~~39.~~ isolated ¹⁰

The cell of claim ~~38~~, wherein said heterologous gene product provides anti-tumor activity in the cells of said tissue.

^{Subt}
~~40. A method of producing a virion capable of tissue-specific replication, said virion comprising a tissue-specific transcriptional regulatory sequence operably linked to the coding region of a gene that is essential for replication of said virion, comprising culturing the cell of claim 30 and recovering said virion from said cell.~~

add
a2

47